Table 3.
Analysis of variables predicting treatment efficacy of 363 renal tumors
| Variables | Treatment efficacy after primary ablation (n = 348) | No treatment efficacy after primary ablation (n = 15) | p-value |
|---|---|---|---|
| Center | 0.48 | ||
| n. 1 (n, %) | 135 (95.1%) | 7 (4.9%) | |
| n. 2 (n, %) | 66 (98.5%) | 1 (1.5%) | |
| n. 3 (n, %) | 75 (93.8%) | 5 (6.3%) | |
| n. 4 (n, %) | 69 (97.2%) | 2 (2.8%) | |
| Gender | 0.28 | ||
| Male (n, %) | 253 (96.6%) | 9 (3.4%) | |
| Female (n, %) | 95 (94.1%) | 6 (5.9%) | |
| Age | 0.73 | ||
| Median (Min–Max) | 74.6 (39.1–89.4) | 75.6 (45.6–89.6) | |
| BMI | 0.63 | ||
| Median (Min–Max) | 26.2 (18.6–40.1) | 27.1 (20.5–37.4) | |
| ASA score | 0.02* | ||
| <4 (n, %) | 336 (96.6%) | 12 (3.4%) | |
| > = 4 (n, %) | 12 (80.0%) | 3 (20.0%) | |
| Single kidney or transplanted kidney | 0.02* | ||
| Yes (n, %) | 43 (89.6 %) | 5 (10.4%) | |
| No (n, %) | 305 (96.8%) | 10 (3.2%) | |
| History of RCC | 0.71 | ||
| No (n, %) | 274 (96.1 %) | 11 (3.0%) | |
| Yes (n, %) | 43 (95.6%) | 2 (4.4%) | |
| Hereditary syndrome (n, %) | 31 (94.0 %) | 2 (6.0%) | |
| Tumor size (mm) | 0.002* | ||
| Median (Min–Max) | 24 (6–53) | 34 (15–50) | |
| <25 mm (n, %) | 176 (98.9%) | 2 (1.1%) | |
| > = 25 mm (n, %) | 172 (93.0%) | 13 (7.0%) | |
| Location | 0.21 | ||
| Endophytic (n, %) | 73 (96.1%) | 3 (3.9%) | |
| Esophytic (n, %) | 162 (97.6%) | 4 (2.4%) | |
| Partially esophytic (n, %) | 113 (93.4%) | 8 (6.6%) | |
| Padua score | 0.01* | ||
| Median (Min–Max) | 8 (6–12) | 9 (7–11) | |
| <9 (n, %) | 247 (97.6%) | 6 (2.4%) | |
| > = 9 (n, %) | 101 (91.8%) | 9 (8.2%) | |
| Number of tumors for treatment session | 0.25 | ||
| 1 (n, %) | 327 (96.2%) | 13 (3.8%) | |
| >1 (n, %) | 21 (91.3%) | 2 (8.7%) | |
| Anesthesia | 0.93 | ||
| Local (n, %) | 74 (97.4%) | 2 (2.6%) | |
| Sedation (n, %) | 223 (95.3%) | 11 (4.7%) | |
| General–Laparo (n, %) | 22 (95.7%) | 1 (4.3%) | |
| General–Percutaneous (n, %) | 29 (96.7%) | 1 (3.3%) | |
| Approach | 0.96 | ||
| Percutaneous (n, %) | 326 (95.9%) | 14 (4.1%) | |
| Laparoscopic (n, %) | 22 (95.7%) | 1 (4.3 %) | |
| Number of cryoprobes | 0.02* | ||
| Median (Min–Max) | 2 (1–8) | 3 (2–7) | |
| < = 2 (n, %) | 217 (97.8%) | 5 (2.2%) | |
| >2 (n, %) | 131 (92.9%) | 10 (7.1%) | |
| Baseline Serum Creatinine (mg/dl) | 0.10 | ||
| Median (Min–Max) | 1.01 (0.50–6.2) | 1.01 (0.51–7.0) | |
| Baseline Serum Creatinine** | 0.18 | ||
| <1.30 mg/dl (n, %) | 265 (96.7%) | 9 (3.3%) | |
| > = 1.30 mg/dl (n, %) | 69 (93.2%) | 5 (6.8%) |
RCC Renal Cell Carcinoma, BMI Body Mass Index, ASA American Society of Anesthesiology
**15 missing data